Claims for Patent: 9,125,939

Summary for Patent: 9,125,939

Title:	Carbostyril derivatives and mood stabilizers for treating mood disorders
Abstract:	The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-sero-tonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamaza-pine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
Inventor(s):	Kikuchi; Tetsuro (Tokushima, JP), Iwamoto; Taro (Princeton, NJ), Hirose; Tsuyoshi (Tokushima, JP)
Assignee:	Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	10/556,600
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,125,939
Patent Claims:	1. A method of treating bipolar disorder in a patient partially nonresponsive to lithium or valproic acid, divalproex sodium or a salt thereof monotherapy comprising: administering an amount of a composition comprising aripiprazole, and lithium or a salt thereof in a pharmaceutically acceptable carrier, wherein the amount of lithium is about 0.01 to 500 parts by weight and the amount of aripiprazole is about 1 part by weight, wherein the bipolar disorder is chosen from bipolar disorder I, bipolar disorder II, bipolar disorder with or without psychotic features, mania, acute mania, bipolar depression, and mixed episodes. 2. A method of treating bipolar disorder in a patient partially nonresponsive to lithium or valproic acid, divalproex sodium or a salt thereof monotherapy comprising: administering separately a first amount of aripiprazole, and a second amount of lithium, wherein the amount of lithium is about 0.01 to 500 parts by weight and the amount of aripiprazole is about 1 part by weight, wherein the bipolar disorder is chosen from bipolar disorder I, polar disorder II, bipolar disorder with or without psychotic features, mania, acute mania, bipolar depression, and mixed episodes. 3. The method of claim 1, wherein aripiprazole is anhydrous aripiprazole crystals B. 4. The method of claim 1, wherein the bipolar disorder is bipolar disorder I. 5. The method of claim 1, wherein the bipolar disorder is mania with bipolar disorder I. 6. The method of claim 2, wherein the bipolar disorder is bipolar disorder II. 7. The method of claim 2, wherein the bipolar disorder is mania with bipolar disorder I. 8. The method of claim 1, wherein the bipolar disorder is mixed episode associated with bipolar disorder I. 9. The method of claim 2, wherein the bipolar disorder is mixed episode associated with bipolar disorder I. 10. The method of claim 2, wherein aripiprazole is anhydrous aripiprazole crystals B.